Absence of Circadian Expression Patterns of Genes Involved in Apoptosis in Peripheral Blood Cells of Cushing Syndrome Patients before and after Surgical Cure

2011 ◽  
pp. P3-514-P3-514
Author(s):  
Aleta Hong ◽  
Qingxiang Wei ◽  
Peter J Munson ◽  
Yanqin Yang ◽  
Nalini Raghavachari ◽  
...  
2015 ◽  
Vol 64 (11) ◽  
pp. 1437-1447 ◽  
Author(s):  
Sara J. Felts ◽  
Virginia P. Van Keulen ◽  
Adam D. Scheid ◽  
Kathleen S. Allen ◽  
Renee K. Bradshaw ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-14 ◽  
Author(s):  
Guangxi Zhou ◽  
Lin Yu ◽  
Wenjing Yang ◽  
Wei Wu ◽  
Leilei Fang ◽  
...  

Background. Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronically remittent and progressive inflammatory disorders. Phospholipase D2 (PLD2) is reported to be involved in the pathogenesis of several inflammatory diseases. However, the exact role of PLD2 in IBD is obscure.Methods. PLD2 expression was determined in peripheral blood cells and inflamed mucosa from patients with IBD by qRT-PCR. Colonic biopsies were also obtained from CD patients before and after infliximab (IFX) treatment to examine PLD2 expression. PLD2 selective inhibitor (CAY10594) was administrated daily by oral gavage in DSS-induced colitis mice. Bone marrow neutrophils from colitis mice were harvested to examine the migration using Transwell plate.Results. PLD2 was found to be significantly increased in peripheral blood cells and inflamed mucosa in patients with active IBD. Treatment with IFX could significantly decrease PLD2 expression in intestinal mucosa in patients with CD. Moreover, blockade of PLD2 with CAY10594 could markedly ameliorate DSS-induced colitis in mice and promote neutrophil migration.Conclusions. PLD2 plays a critical role in the pathogenesis of IBD. Blockade of PLD2 may serve as a new therapeutic approach for treatment of IBD.


1997 ◽  
Vol 21 (5) ◽  
pp. 449-452 ◽  
Author(s):  
Adriano Antonucci ◽  
Angela Di Baldassarre ◽  
Franco Di Giacomo ◽  
Liborio Stuppia ◽  
Giandomenico Palka

2005 ◽  
Vol 7 (5) ◽  
Author(s):  
Praveen Sharma ◽  
Narinder S Sahni ◽  
Robert Tibshirani ◽  
Per Skaane ◽  
Petter Urdal ◽  
...  

2016 ◽  
Vol 39 (7) ◽  
pp. 1085-1090 ◽  
Author(s):  
Hideyuki Kushihara ◽  
Takafumi Kuzuya ◽  
Yuko Miwa ◽  
Kenta Iwasaki ◽  
Yoshihiko Watarai ◽  
...  

1987 ◽  
Vol 58 (03) ◽  
pp. 936-942 ◽  
Author(s):  
Lindsey A Miles ◽  
Edward F Plow

SummaryGlu-plasminogen binds to platelets; the monocytoid line, U937, and the human fetal fibroblast line, GM1380 bind both plasminogen and its activator, urokinase. This study assesses the interaction of these fibrinolytic proteins with circulating human blood cells. Plasminogen bound minimally to red cells but bound saturably and reversibly to monocytes, granulocytes and lymphocytes with apparent Kd values of 0.9-1.4 μM. The interactions were of high capacity with 1.6 to 49 × 105 sites/cell and involved the lysine binding sites of plasminogen. Both T cells and non-rosetting lymphocytes and two B cell lines saturably bound plasminogen. Urokinase bound saturably to gianulocytes, monocytes, non-rosetting lymphocytes and a B cell line, but minimally to T cells, platelets and red cells. Therefore, plasminogen binding sites of high capacity, of similar affinities, and with common recognition specificities are expressed by many peripheral blood cells. Urokinase receptors are also widely distributed, but less so than plasminogen binding sites. The binding ol plasminogen and/ or urokinase to these cells may lead to generation of cell- associated proteolytic activity which contributes to a variety of cellular functions.


Sign in / Sign up

Export Citation Format

Share Document